SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is experiencing extreme volatility as traders react to escalating geopolitical tensions in the Middle East, characterized by drone strikes and renewed hostilities. The community is actively debating whether ongoing reports of potential peace deals are genuine or merely market-manipulation tactics intended to suppress oil prices ahead of key economic events.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The SPY is trending as market participants react to conflicting signals regarding geopolitical tensions in the Middle East and a purported peace deal, which many in the community view with skepticism. Traders are actively debating whether these developments represent a genuine shift in market dynamics or another example of speculative volatility driven by leadership rhetoric.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is at the center of intense market focus as investors await earnings due after Monday's market close, with community sentiment divided between bullish anticipation of continued AI-driven revenue growth and concerns over high valuation. Traders are closely monitoring the stock's consolidation above key support levels, viewing the upcoming report as a critical catalyst that could determine whether the stock breaks out or faces further downside volatility.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb is trending as investors weigh potential M&A activity against the company's efforts to replace revenue from key drugs facing patent cliffs. Community discussion is focused on the impact of upcoming pipeline readouts, strategic AI collaborations, and the company's positioning as a defensive dividend play amidst broader market volatility.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing intense volatility driven by speculative anticipation surrounding potential supply burns, exchange re-listings, and major governance voting updates. The community remains deeply polarized, split between those betting on an underdog turnaround fueled by social media sentiment and skeptics who view the token as a high-risk relic of past market failures.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.

Cardano

Cardano is trending amid intense debate over its long-term viability, with vocal bulls aggressively accumulating tokens at current lows while critics dismiss the project as a failing 'ghost chain' due to limited adoption and leadership controversies. The community remains deeply polarized, frequently citing potential regulatory catalysts like the Clarity Act versus the risks posed by recent security concerns and persistent price weakness.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is trending as it secures a major three-year tariff exemption from the U.S. administration by committing to significant domestic manufacturing investments and adopting "most-favored nation" drug pricing. The community is actively discussing the stock's potential for a rally driven by this favorable political development and the company's strong oncology pipeline.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending as market participants debate its long-term potential against a backdrop of technical volatility and persistent community chatter regarding accumulation zones. Supporters point to institutional interest and post-quantum security advancements as key drivers, while skeptics remain focused on past performance and historical price levels.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

Gold is currently trending as investors debate whether the recent pullback represents a major generational buying opportunity or the beginning of a multi-year downtrend. The community is actively discussing the impact of high interest rates, rising national debt, and geopolitical tensions, with many seeking confirmation of a bottom through technical support levels and volume patterns.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors eagerly await the imminent IZAR-1 clinical trial results, with sentiment heavily focused on the company's timeline for data release. The community remains divided between optimistic speculation regarding potential buyout activity or best-in-class efficacy and frustration over the perceived lack of communication regarding specific catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes OKYO Pharma (OKYO) a New Buy Stock

OKYO Pharma (OKYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Average Rating of "Hold" from Analysts

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) has earned an average recommendation of 'Hold' from the five analysts that are presently covering the firm, MarketBeat.com reports...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Up 31.9% in April

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling 272,194 shares, an increase of 31.9% from the March 31st total of 206,345 shares. Based on...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 25.0% in March

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 31st, there was short interest...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Average Recommendation of "Hold" by Brokerages

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have been given an average rating of "Hold" by the five analysts that are covering the firm, Marketbeat.com reports. One...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a large drop in short interest during the month of March. As of March 13th, there was short interest totaling...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 12.4% in February

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a significant drop in short interest in February. As of February 27th, there was short interest totaling 435,430...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Consensus Rating of "Hold" from Analysts

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have received a consensus rating of "Hold" from the five analysts that are covering the firm, Marketbeat.com reports. One...

OKYO Pharma (NASDAQ:OKYO) Raised to "Strong-Buy" at Piper Sandler

Piper Sandler raised OKYO Pharma to a "strong-buy" rating in a report on Friday...

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have earned a consensus rating of "Hold" from the five ratings firms that are presently covering the firm, MarketBeat.com...

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It operates through the US and UK geographical segments. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Limited - Ordinary Shares - New

OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

OKYOPharma Limited

Fundamentals

Connect Stocktwits to ChatGPT

Latest OKYO News